{"gene":"TRIP12","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":2012,"finding":"TRIP12 and UBR5, two HECT domain E3 ubiquitin ligases, control accumulation of RNF168 by promoting its degradation via ubiquitylation, thereby limiting spreading of histone ubiquitin conjugates (H2A-Ub) beyond DNA double-strand break sites and preventing hyperaccumulation of 53BP1 and BRCA1 at undamaged chromatin.","method":"siRNA depletion of TRIP12/UBR5, immunofluorescence of 53BP1/BRCA1/ubiquitin conjugates, western blot for RNF168 levels, DSB-induced focus formation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal depletion experiments with multiple orthogonal readouts, replicated across labs (>297 citations)","pmids":["22884692"],"is_preprint":false},{"year":2008,"finding":"TRIP12 HECT domain functions as the E3 ubiquitin ligase of the human ubiquitin fusion degradation (UFD) pathway, catalyzing in vitro ubiquitination of UFD substrates (including UBB+1) in conjunction with E1, E2, and E4 enzymes; the HECT domain possesses a noncovalent ubiquitin-binding site required for substrate recognition.","method":"In vitro ubiquitination assay, siRNA knockdown, cell death assays, cross-linking of HECT domain to ubiquitin moiety in vivo, complementation with HECT domain alone","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and cross-linking; multiple orthogonal methods in single paper","pmids":["19028681"],"is_preprint":false},{"year":2008,"finding":"TRIP12 interacts with APP-BP1 (NEDD8-activating enzyme subunit) specifically as a monomer (not as APP-BP1/Uba3 heterodimer), ubiquitinates it in vitro requiring E4 activity for polyubiquitination, and promotes its proteasomal degradation, thereby modulating neddylation of CUL1.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro ubiquitination assay, siRNA knockdown with western blot, neddylation assay of CUL1","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro ubiquitination reconstitution plus multiple cellular assays","pmids":["18627766"],"is_preprint":false},{"year":2011,"finding":"The E3 ubiquitin ligase activity of Trip12 is indispensable for mouse embryogenesis; homozygous catalytic inactivation causes embryonic lethality with growth arrest and p16 upregulation; Trip12 targets BAF57 (SWI/SNF component) for degradation and regulates global gene expression.","method":"Homozygous knock-in mutation disrupting HECT catalytic activity, mouse embryology, ES cell growth and differentiation assays, western blot for BAF57 and p16","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with defined in vivo phenotype and molecular substrate identification","pmids":["22028794"],"is_preprint":false},{"year":2012,"finding":"HUWE1 and TRIP12 function in parallel (additive stabilization upon double knockdown) during UFD substrate degradation; HUWE1 associates with both the UFD substrate Ub(G76V)-YFP and the 26S proteasome, acting late in the pathway.","method":"High-throughput siRNA imaging screen, single/double knockdown, pulse-chase degradation assays, co-immunoprecipitation with proteasome","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis by double knockdown; single lab but orthogonal approaches","pmids":["23209776"],"is_preprint":false},{"year":2016,"finding":"TRIP12 functions as an E3 ubiquitin ligase for USP7/HAUSP, controlling its protein stability; TRIP12 knockdown increases USP7-mediated stabilization of p53, 53BP1, and Chk1 and increases the G1 cell population, while TRIP12 overexpression phenocopies USP7 knockdown by increasing intra-S phase cells.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression, western blot, cell cycle analysis by FACS","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, co-IP plus knockdown/overexpression with cell cycle phenotype","pmids":["27800609"],"is_preprint":false},{"year":2020,"finding":"TRIP12 binds PARP1 via its central PAR-binding WWE domain and, via its C-terminal HECT domain, catalyzes polyubiquitylation of PARP1 triggering proteasomal degradation; loss of TRIP12 elevates PARP1 levels, causing increased PARPi-induced cytotoxic PARP1 trapping, replication stress, and cell death.","method":"Co-immunoprecipitation, in vitro ubiquitination, siRNA knockdown, PARP1 trapping assay, cell viability/clonogenic survival, domain mapping (WWE and HECT)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — domain-level mechanistic dissection with in vitro ubiquitination plus multiple cellular phenotypes","pmids":["32755579"],"is_preprint":false},{"year":2021,"finding":"TRIP12 promotes PROTAC/CRL2VHL-induced degradation of neo-substrate BRD4 (but not endogenous HIF-1α) by associating with BRD4 via CRL2VHL and specifically assembling K29-linked ubiquitin chains that facilitate formation of K29/K48-branched ubiquitin chains, accelerating K48 chain elongation and proteasomal degradation.","method":"Mass spectrometry-based ubiquitin linkage analysis, in vitro ubiquitination, siRNA/CRISPR knockout, PROTAC degradation assays, domain mapping, apoptosis assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with MS-based chain linkage determination and multiple orthogonal cellular assays","pmids":["33567268"],"is_preprint":false},{"year":2021,"finding":"TRIP12 interacts with glucocerebrosidase (GCase) and ubiquitinates it at lysine 293, triggering proteasomal degradation; TRIP12 overexpression causes premature GCase degradation, α-synuclein accumulation, and mitochondrial dysfunction; conditional TRIP12 knockout or knockdown promotes GCase expression and blocks dopaminergic neurodegeneration in PD models.","method":"Co-immunoprecipitation, in vitro ubiquitination, site-directed mutagenesis (K293), TRIP12 conditional KO mouse, in vivo knockdown, α-syn PFF model, western blot, human PD brain tissue analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — site-specific ubiquitination with mutagenesis, in vivo KO and knockdown, multiple orthogonal methods","pmids":["34644545"],"is_preprint":false},{"year":2021,"finding":"TRIP12 ubiquitinates FBW7 preferentially on K404/K412 (via SCFFBW7 self-ubiquitylation) and additionally assembles K11-linked branched ubiquitin chains on FBW7 via its HECT domain; this branched ubiquitylation is required for FBW7 proteasomal degradation; TRIP12 inactivation causes FBW7 accumulation and consequent MCL1 degradation, sensitizing cells to anti-tubulin chemotherapy.","method":"shRNA library screen, mass spectrometry, in vitro ubiquitination, site-directed mutagenesis of FBW7 K404/K412, CRISPR knockout, western blot, cell viability assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — MS-defined chain linkage, mutagenesis, in vitro ubiquitination, genetic epistasis","pmids":["33824312"],"is_preprint":false},{"year":2020,"finding":"TRIP12 expression is regulated during the cell cycle correlating with its nuclear localization; an N-terminal intrinsically disordered region (IDR) mediates euchromatin binding; TRIP12 controls duration of DNA replication (mitotic entry) independent of its catalytic activity, and is required for mitotic progression and chromosome stability.","method":"Cell cycle synchronization, western blot, immunofluorescence/live imaging, chromatin fractionation, siRNA knockdown, catalytic mutant complementation, FACS for chromosome stability","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with functional consequence; catalytic mutant separates enzymatic from non-enzymatic roles","pmids":["31964993"],"is_preprint":false},{"year":2021,"finding":"WARS (tryptophanyl-tRNA synthetase) tryptophanylates TRIP12 at lysine 1136, activating its E3 ligase activity toward NFATc1 (a PD-1 transcription activator), promoting NFATc1 degradation and reducing PD-1 surface expression on CD8+ T cells; SIRT1 de-tryptophanylates TRIP12 and reverses these effects.","method":"Mass spectrometry identification of tryptophanylation, site-directed mutagenesis (K1136), co-immunoprecipitation, flow cytometry for surface PD-1, syngeneic mouse tumor models","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — novel PTM identified by MS with mutagenesis validation and downstream functional consequence","pmids":["34326168"],"is_preprint":false},{"year":2020,"finding":"TRIP12 is identified by immunoprecipitation-coupled LC-MS/MS as an E3 ubiquitin ligase that binds and ubiquitinates the transcription factor YY1, leading to its proteasomal degradation; this triggers the HNF4α/miR-122/CCL2 pathway promoting hepatic inflammation during mild iron overload.","method":"Immunoprecipitation coupled LC-MS/MS, co-immunoprecipitation, western blot, siRNA knockdown, overexpression in vivo","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — substrate identification by IP-MS with functional validation in vivo; single lab","pmids":["33080340"],"is_preprint":false},{"year":2023,"finding":"TRIP12 controls TGFβ signaling in a manner completely independent of its E3 ubiquitin ligase activity; instead, TRIP12 recruits SMURF2 to SMAD4, promoting inhibitory monoubiquitination of SMAD4; catalytically inactive C1959A mutant rescues TRIP12-KO phenotype; this function is evolutionarily conserved (Drosophila ctrip/Medea epistasis confirmed).","method":"CRISPR/Cas9 KO, catalytic mutant complementation (C1959A), co-immunoprecipitation of SMURF2-SMAD4, TGFβ reporter assays, Drosophila genetic epistasis, 3D intestinal organoids, migration assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — catalytic mutant demonstrates ligase-independent function; epistasis in two organisms; multiple orthogonal methods","pmids":["37863914"],"is_preprint":false},{"year":2025,"finding":"TRIP12 ubiquitylates DNA polymerase β (Polβ) in a BER complex-dependent manner, controlling Polβ cellular levels and chromatin loading; TRIP12-mediated Polβ ubiquitylation promotes Polβ foci formation at radiation-induced DNA damage sites, directing BER over DSB repair; excessive TRIP12-mediated Polβ engagement increases DSB formation and radiation sensitivity.","method":"Ubiquitination assays, chromatin fractionation, siRNA/CRISPR depletion, Polβ foci formation (immunofluorescence), radiation sensitivity/clonogenic assays, co-immunoprecipitation","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods; single lab but rigorous mechanistic dissection","pmids":["40613707"],"is_preprint":false},{"year":2025,"finding":"TRIP12 ubiquitylates BRG1 (SWI/SNF component) in the presence of Wnt signaling, promoting BRG1 interaction with β-catenin in the nucleus to recruit SWI/SNF to Wnt target genes; TRIP12 depletion attenuates Wnt signaling; genetic epistasis places TRIP12 downstream of the β-catenin destruction complex.","method":"CRISPR/siRNA depletion in Drosophila, zebrafish, mouse organoids, human cells; co-immunoprecipitation of BRG1-β-catenin; ubiquitination assays; genetic epistasis; Wnt reporter assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — epistasis across multiple organisms, co-IP, ubiquitination assays, multiple orthogonal systems","pmids":["40473626"],"is_preprint":false},{"year":2025,"finding":"TRIP12 functions as a ubiquitin chain elongation factor that cooperates with CUL3KEAP1 to ensure robust NRF2 degradation; TRIP12 activity accelerates silencing of the oxidative stress response as ROS are cleared but limits NRF2 activation during stress.","method":"CRISPR KO, NRF2 degradation assays, ubiquitin chain assays, oxidative stress/ROS assays, cell viability after oxeiptosis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with mechanistic chain elongation assays; single lab","pmids":["40928944"],"is_preprint":false},{"year":2025,"finding":"TRIP12 ubiquitinates Frizzled-9b (Fzd9b) at K437 in its third intracellular loop, targeting it for lysosomal degradation, reducing Fzd9b membrane surface expression and dampening Wnt9a/Fzd9b signaling; this semi-selective action affects hematopoietic stem cell proliferation in zebrafish.","method":"Site-directed mutagenesis of Fzd9b K437, ubiquitination assays, flow cytometry for surface Fzd9b, zebrafish HSC proliferation assay, lysosome inhibitor experiments, co-immunoprecipitation","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — site-specific ubiquitination with mutagenesis plus in vivo zebrafish functional readout","pmids":["41098776"],"is_preprint":false},{"year":2024,"finding":"K29-linked ubiquitylation of SUV39H1 (H3K9me3 methyltransferase) is catalyzed by TRIP12 and reversed by TRABID; K29-linked ubiquitylation is essential for proteasomal degradation of SUV39H1 even in the presence of extensive K48-linked ubiquitylation; disruption of this modification deregulates the H3K9me3 landscape.","method":"Ubiquitin replacement cell-based strategy, MS-based linkage analysis, TRIP12 KO/depletion, in vitro ubiquitination, H3K9me3 ChIP, SUV39H1 stability assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro reconstitution and MS linkage analysis; preprint, single lab","pmids":["bio_10.1101_2024.10.29.620783"],"is_preprint":true},{"year":2023,"finding":"TRIP12 suppresses EMT through inhibiting ZEB1/2 gene expression; TRIP12-depleted cells gain mesenchymal traits (loss of polarity, increased motility, anoikis resistance); ZEB1/2 depletion rescues EMT markers in TRIP12-depleted cells, placing ZEB1/2 downstream of TRIP12.","method":"siRNA knockdown of TRIP12, RNA-seq, ZEB1/2 double KD rescue, cell polarity assays, migration assays, anoikis assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis by rescue experiment with defined cellular phenotypes","pmids":["33963176"],"is_preprint":false},{"year":2016,"finding":"p16 overexpression downregulates TRIP12, which leads to increased RNF168 levels, repressed DNA damage repair, increased 53BP1 foci, and enhanced radiosensitivity; TRIP12 inhibition further radiosensitizes cells, establishing a p16→TRIP12→RNF168 regulatory axis.","method":"p16 overexpression/shRNA knockdown, western blot for TRIP12 and RNF168, immunofluorescence for 53BP1 foci, clonogenic survival assays, neutral comet assay, cycloheximide half-life assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — defined epistatic pathway with multiple orthogonal cellular readouts","pmids":["27425591"],"is_preprint":false},{"year":2023,"finding":"TRIP12 associates with Ku70 at sites of DNA double-strand breaks; this association is enhanced upon ionizing radiation and is specific to the Ku70 S155 phosphorylated form, as identified by BioID2 proximity labeling and validated by proximity ligation assay and co-immunoprecipitation.","method":"BioID2 proximity labeling, SAINTexpress analysis, proximity ligation assay (PLA), co-immunoprecipitation after IR treatment","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 — proximity labeling with PLA validation; no functional consequence established for TRIP12","pmids":["37108203"],"is_preprint":false},{"year":2026,"finding":"The N-terminal intrinsically disordered region (IDR) of TRIP12 drives formation of dynamic chromatin condensates enriched in heterochromatin marks through electrostatic interactions and bridging-induced phase separation; these condensates alter cell cycle progression, genome accessibility, and transcription independently of TRIP12's ubiquitin ligase activity.","method":"Live-cell imaging, FRAP, IDR deletion/mutation constructs, heterochromatin mark staining, ATAC-seq, transcriptome analysis, catalytic mutant controls","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with functional consequences; catalytic mutant separates enzymatic from phase-separation roles","pmids":["41660270"],"is_preprint":false}],"current_model":"TRIP12 is a HECT-domain E3 ubiquitin ligase that assembles multiple ubiquitin chain topologies (K29, K11, K48, and branched chains) to target diverse substrates—including RNF168, PARP1, FBW7, GCase, USP7, YY1, Polβ, BRG1, Fzd9b, NRF2, and UFD pathway substrates—for proteasomal or lysosomal degradation, while also exerting ligase-independent functions by recruiting SMURF2 to SMAD4 to suppress TGFβ signaling and by using its N-terminal IDR to drive chromatin condensate formation, thereby regulating DNA damage responses, cell cycle progression, Wnt signaling, and the oxidative stress response."},"narrative":{"teleology":[{"year":2008,"claim":"Establishing TRIP12 as the dedicated E3 ligase of the ubiquitin fusion degradation (UFD) pathway resolved how aberrant ubiquitin-fusion proteins are recognized and cleared, and revealed a noncovalent ubiquitin-binding site in the HECT domain required for substrate engagement.","evidence":"In vitro ubiquitination reconstitution with HECT domain mutagenesis, cross-linking, and siRNA knockdown in human cells","pmids":["19028681"],"confidence":"High","gaps":["E4 cofactor identity for UFD pathway elongation not fully defined","Structural basis of the noncovalent ubiquitin-binding site unresolved"]},{"year":2008,"claim":"Demonstration that TRIP12 ubiquitinates APP-BP1 (a NEDD8-activating enzyme subunit) and controls its proteasomal turnover linked TRIP12 to regulation of the neddylation cascade, expanding its role beyond UFD substrates.","evidence":"Yeast two-hybrid, co-immunoprecipitation, in vitro ubiquitination, and siRNA knockdown with CUL1 neddylation readout","pmids":["18627766"],"confidence":"High","gaps":["Whether TRIP12 regulation of neddylation has physiological consequences in vivo not tested","E4 requirement for APP-BP1 polyubiquitination not molecularly defined"]},{"year":2011,"claim":"Genetic inactivation of Trip12 catalytic activity in mice established that its E3 ligase function is essential for embryogenesis, identified BAF57 (SWI/SNF subunit) as an in vivo substrate, and linked TRIP12 loss to p16 de-repression.","evidence":"Homozygous knock-in catalytic-dead mutation in mice; ES cell assays; western blot for BAF57 and p16","pmids":["22028794"],"confidence":"High","gaps":["Whether p16 is a direct or indirect TRIP12 target not resolved","Tissue-specific requirements during embryogenesis not defined"]},{"year":2012,"claim":"Discovery that TRIP12 (and UBR5) limit RNF168 accumulation to prevent excessive histone ubiquitylation spreading at DNA damage sites established TRIP12 as a rheostat for the DNA damage response, explaining how 53BP1 and BRCA1 foci are confined to break-proximal chromatin.","evidence":"siRNA depletion of TRIP12/UBR5 with immunofluorescence for 53BP1/BRCA1/ubiquitin conjugates and RNF168 protein level measurement","pmids":["22884692"],"confidence":"High","gaps":["Whether TRIP12 directly ubiquitinates RNF168 in vitro not shown in this study","Relative contributions of TRIP12 versus UBR5 not fully deconvolved"]},{"year":2016,"claim":"Identification of USP7 as a TRIP12 substrate linked TRIP12 to control of p53 stability and cell cycle transitions, revealing that TRIP12 indirectly tunes the p53 axis by degrading a key deubiquitinase.","evidence":"Co-immunoprecipitation, siRNA knockdown, overexpression, and FACS cell cycle analysis","pmids":["27800609"],"confidence":"Medium","gaps":["In vitro ubiquitination of USP7 by TRIP12 not demonstrated","Direct ubiquitination sites on USP7 not mapped"]},{"year":2020,"claim":"Mapping TRIP12's WWE domain as the PAR-binding module that targets PARP1 for HECT-dependent ubiquitylation and degradation explained how TRIP12 loss sensitizes cells to PARP inhibitors through increased PARP1 trapping, providing a pharmacologically actionable mechanism.","evidence":"Domain mapping, in vitro ubiquitination, PARP1 trapping assay, clonogenic survival after PARPi treatment","pmids":["32755579"],"confidence":"High","gaps":["Chain linkage specificity on PARP1 not determined","Whether PAR binding is required for all TRIP12 substrates unclear"]},{"year":2020,"claim":"Characterization of cell-cycle-dependent TRIP12 expression and its N-terminal IDR-mediated euchromatin association revealed a catalytic-activity-independent role in controlling DNA replication timing and mitotic entry, separating enzymatic from structural functions.","evidence":"Cell cycle synchronization, chromatin fractionation, catalytic mutant complementation, live imaging","pmids":["31964993"],"confidence":"Medium","gaps":["Molecular mechanism by which IDR binding to chromatin controls replication timing unknown","Whether IDR function requires specific chromatin readers not tested"]},{"year":2021,"claim":"Demonstration that TRIP12 assembles K29-linked chains that seed K29/K48-branched ubiquitin chains on substrates (shown for PROTAC-recruited BRD4) established TRIP12 as a ubiquitin chain architecture specialist that accelerates proteasomal targeting through branched chain formation.","evidence":"Mass spectrometry-based ubiquitin linkage analysis, in vitro ubiquitination reconstitution, CRISPR KO, PROTAC degradation assays","pmids":["33567268"],"confidence":"High","gaps":["Whether K29/K48 branching is a general feature of all TRIP12 substrates not known","Structural basis for K29 linkage preference not resolved"]},{"year":2021,"claim":"Identification of glucocerebrosidase (GCase) K293 as a TRIP12 ubiquitination site linked TRIP12 to Parkinson's disease pathogenesis: TRIP12-driven GCase degradation causes α-synuclein accumulation and dopaminergic neurodegeneration, reversible by TRIP12 conditional knockout.","evidence":"Site-directed mutagenesis, conditional KO mouse, α-synuclein PFF model, human PD brain tissue analysis","pmids":["34644545"],"confidence":"High","gaps":["Whether TRIP12 inhibition is therapeutically viable for PD not tested in primates","Upstream signals controlling TRIP12-GCase interaction unknown"]},{"year":2021,"claim":"Revealing that TRIP12 builds K11-branched ubiquitin chains on FBW7 (at K404/K412) to drive its degradation connected TRIP12 to indirect stabilization of MCL1 and chemotherapy resistance, providing a mechanistic basis for TRIP12 inactivation as a sensitization strategy.","evidence":"shRNA library screen, MS-based linkage analysis, in vitro ubiquitination, FBW7 mutagenesis, CRISPR KO","pmids":["33824312"],"confidence":"High","gaps":["Whether K11-branched chains are assembled by TRIP12 alone or require an E4 cofactor not fully resolved","Quantitative contribution of FBW7 self-ubiquitylation priming versus TRIP12-initiated ubiquitylation unclear"]},{"year":2023,"claim":"Demonstration that TRIP12 suppresses TGF-β signaling entirely independently of its catalytic activity—by recruiting SMURF2 to monoubiquitinate SMAD4—established a paradigm-shifting non-enzymatic adaptor function conserved from Drosophila to mammals.","evidence":"Catalytic mutant C1959A rescue of TRIP12-KO phenotype, co-IP of SMURF2-SMAD4, TGF-β reporter assays, Drosophila ctrip/Medea genetic epistasis","pmids":["37863914"],"confidence":"High","gaps":["Binding interface between TRIP12 and SMURF2 not structurally resolved","Whether this adaptor function extends to other signaling pathways unknown"]},{"year":2023,"claim":"Establishing that TRIP12 depletion induces EMT through ZEB1/2 upregulation positioned TRIP12 as a suppressor of mesenchymal transition, though whether this occurs through direct ZEB1/2 ubiquitination or an indirect transcriptional mechanism remains open.","evidence":"siRNA knockdown, RNA-seq, ZEB1/2 double-KD rescue of EMT markers, migration and anoikis assays","pmids":["33963176"],"confidence":"Medium","gaps":["Whether ZEB1/2 are direct TRIP12 substrates not determined","Contribution of TRIP12 ligase activity versus adaptor function to EMT suppression not tested"]},{"year":2025,"claim":"Discovery that TRIP12 ubiquitylates Pol-β in a BER-complex-dependent manner, promoting its chromatin loading at damage sites to favor base excision repair over DSB repair, revealed TRIP12 as a repair pathway choice factor whose overactivity paradoxically increases DSBs and radiosensitivity.","evidence":"Ubiquitination assays, chromatin fractionation, Pol-β foci formation after IR, clonogenic survival, CRISPR depletion","pmids":["40613707"],"confidence":"Medium","gaps":["Ubiquitin chain type on Pol-β not identified","Whether this mechanism operates in non-irradiated cells during normal BER not tested"]},{"year":2025,"claim":"Showing that TRIP12 ubiquitylates BRG1 to promote its interaction with β-catenin at Wnt target genes—conserved across Drosophila, zebrafish, mouse, and human cells—placed TRIP12 as a positive regulator of canonical Wnt signaling acting downstream of the β-catenin destruction complex.","evidence":"CRISPR/siRNA in four model organisms, co-IP of BRG1-β-catenin, ubiquitination assays, Wnt reporter assays, genetic epistasis","pmids":["40473626"],"confidence":"High","gaps":["Chain linkage type on BRG1 not determined","Whether TRIP12-mediated BRG1 ubiquitination is degradative or non-degradative not fully clarified"]},{"year":2025,"claim":"Identification of TRIP12 as a ubiquitin chain elongation factor cooperating with CUL3-KEAP1 to degrade NRF2 explained how the oxidative stress response is rapidly silenced once ROS are cleared, adding NRF2 to the catalog of TRIP12 substrates requiring E3–E3 cooperation.","evidence":"CRISPR KO, NRF2 degradation and ubiquitin chain assays, oxidative stress and oxeiptosis cell viability assays","pmids":["40928944"],"confidence":"Medium","gaps":["Chain linkage specificity on NRF2 by TRIP12 not determined","Whether TRIP12 functions similarly with other CRL E3 ligases beyond CUL3-KEAP1 and CRL2-VHL not explored"]},{"year":2026,"claim":"Demonstration that the TRIP12 N-terminal IDR drives chromatin condensate formation through bridging-induced phase separation, independently of catalytic activity, unified earlier observations of IDR-dependent chromatin binding with a biophysical mechanism and showed these condensates alter genome accessibility and transcription.","evidence":"Live-cell imaging, FRAP, IDR deletion/mutation constructs, ATAC-seq, transcriptome analysis, catalytic mutant controls","pmids":["41660270"],"confidence":"Medium","gaps":["Whether condensate formation is required for TRIP12's ligase-dependent functions unknown","Biophysical parameters (valency, saturation concentration) not quantitatively defined","In vivo relevance of condensates in organismal physiology not tested"]},{"year":null,"claim":"A complete structural model of full-length TRIP12 is lacking, and the rules governing substrate selectivity among its many targets—particularly how WWE-domain PAR binding, IDR-mediated chromatin association, and HECT-domain chain-type specificity are coordinated—remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of full-length TRIP12 available","Mechanisms determining K29 versus K11 versus K48 chain selectivity per substrate unknown","How TRIP12 ligase-dependent and ligase-independent functions are spatiotemporally coordinated in vivo not understood"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,3,6,7,8,9,14,15,16,17]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,7,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,22]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[10,22]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,6,14,20]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,10,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2,7,8,9,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,15,17]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[16]}],"complexes":[],"partners":["RNF168","PARP1","FBW7","GBA","SMAD4","SMURF2","BRG1","USP7"],"other_free_text":[]},"mechanistic_narrative":"TRIP12 is a HECT-domain E3 ubiquitin ligase that assembles diverse ubiquitin chain topologies—including K29, K11, K48, and branched chains—to target a broad substrate repertoire for proteasomal or lysosomal degradation, thereby governing DNA damage responses, cell cycle progression, Wnt signaling, TGF-β signaling, and the oxidative stress response. Key substrates include RNF168 (limiting histone ubiquitin spreading at DNA break sites) [PMID:22884692], PARP1 (modulating PARP inhibitor sensitivity) [PMID:32755579], FBW7 (via K11-branched chains controlling MCL1 stability) [PMID:33824312], glucocerebrosidase (regulating α-synuclein accumulation and dopaminergic neuron survival) [PMID:34644545], BRG1 (recruiting SWI/SNF to β-catenin at Wnt target genes) [PMID:40473626], and NRF2 (cooperating with CUL3-KEAP1 to silence the oxidative stress response) [PMID:40928944]. TRIP12 also performs ligase-independent functions: its N-terminal intrinsically disordered region drives chromatin condensate formation that alters genome accessibility and cell cycle timing [PMID:41660270], and it recruits SMURF2 to SMAD4 to suppress TGF-β signaling independently of catalytic activity [PMID:37863914]. Homozygous loss of TRIP12 catalytic activity causes embryonic lethality in mice with growth arrest and p16 upregulation [PMID:22028794]."},"prefetch_data":{"uniprot":{"accession":"Q14669","full_name":"E3 ubiquitin-protein ligase TRIP12","aliases":["E3 ubiquitin-protein ligase for Arf","ULF","HECT-type E3 ubiquitin transferase TRIP12","Thyroid receptor-interacting protein 12","TR-interacting protein 12","TRIP-12"],"length_aa":2067,"mass_kda":228.5,"function":"E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair (PubMed:19028681, PubMed:22884692, PubMed:40419785). Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins (PubMed:19028681). Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PubMed:22884692). In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress (PubMed:20208519). In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation (PubMed:20208519). Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A (PubMed:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation (PubMed:18627766). Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins (PubMed:20829358). Mediates ubiquitination of ASXL1: following binding to N(6)-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex (PubMed:30982744)","subcellular_location":"Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q14669/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRIP12","classification":"Not Classified","n_dependent_lines":161,"n_total_lines":1208,"dependency_fraction":0.13327814569536423},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"NUMA1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TRIP12","total_profiled":1310},"omim":[{"mim_id":"619626","title":"METHYLTRANSFERASE 4, N6-ADENOSINE; METTL4","url":"https://www.omim.org/entry/619626"},{"mim_id":"617752","title":"CLARK-BARAITSER SYNDROME; CLABARS","url":"https://www.omim.org/entry/617752"},{"mim_id":"604506","title":"THYROID HORMONE RECEPTOR INTERACTOR 12; TRIP12","url":"https://www.omim.org/entry/604506"},{"mim_id":"300431","title":"ATKIN-FLAITZ SYNDROME","url":"https://www.omim.org/entry/300431"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear speckles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRIP12"},"hgnc":{"alias_symbol":["KIAA0045","ULF","TRIPC"],"prev_symbol":[]},"alphafold":{"accession":"Q14669","domains":[{"cath_id":"-","chopping":"1117-1233_1465-1504","consensus_level":"high","plddt":88.9245,"start":1117,"end":1504},{"cath_id":"3.10.20.90","chopping":"1255-1311_1342-1369_1387-1402","consensus_level":"medium","plddt":82.6401,"start":1255,"end":1402},{"cath_id":"3.90.1750.10","chopping":"1589-1658_1668-1868","consensus_level":"medium","plddt":90.9303,"start":1589,"end":1868},{"cath_id":"3.30.2410.10","chopping":"1877-1986","consensus_level":"medium","plddt":89.0913,"start":1877,"end":1986}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14669","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14669-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14669-F1-predicted_aligned_error_v6.png","plddt_mean":66.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRIP12","jax_strain_url":"https://www.jax.org/strain/search?query=TRIP12"},"sequence":{"accession":"Q14669","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14669.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14669/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14669"}},"corpus_meta":[{"pmid":"22884692","id":"PMC_22884692","title":"TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22884692","citation_count":297,"is_preprint":false},{"pmid":"32755579","id":"PMC_32755579","title":"The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32755579","citation_count":103,"is_preprint":false},{"pmid":"34326168","id":"PMC_34326168","title":"Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34326168","citation_count":88,"is_preprint":false},{"pmid":"33567268","id":"PMC_33567268","title":"TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33567268","citation_count":74,"is_preprint":false},{"pmid":"19028681","id":"PMC_19028681","title":"The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin fusion degradation pathway.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19028681","citation_count":56,"is_preprint":false},{"pmid":"33198194","id":"PMC_33198194","title":"E3 Ubiquitin Ligase TRIP12: Regulation, Structure, and Physiopathological Functions.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33198194","citation_count":49,"is_preprint":false},{"pmid":"27848077","id":"PMC_27848077","title":"Identification of new TRIP12 variants and detailed clinical evaluation of individuals with non-syndromic intellectual disability with or without autism.","date":"2016","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27848077","citation_count":46,"is_preprint":false},{"pmid":"27800609","id":"PMC_27800609","title":"Trip12 is an E3 ubiquitin ligase for USP7/HAUSP involved in the DNA damage response.","date":"2016","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/27800609","citation_count":42,"is_preprint":false},{"pmid":"28251352","id":"PMC_28251352","title":"Haploinsufficiency of the E3 ubiquitin-protein ligase gene TRIP12 causes intellectual disability with or without autism spectrum disorders, speech delay, and dysmorphic features.","date":"2017","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28251352","citation_count":42,"is_preprint":false},{"pmid":"27425591","id":"PMC_27425591","title":"TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27425591","citation_count":42,"is_preprint":false},{"pmid":"34644545","id":"PMC_34644545","title":"TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.","date":"2021","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/34644545","citation_count":38,"is_preprint":false},{"pmid":"23209776","id":"PMC_23209776","title":"HUWE1 and TRIP12 collaborate in degradation of ubiquitin-fusion proteins and misframed ubiquitin.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23209776","citation_count":35,"is_preprint":false},{"pmid":"22561347","id":"PMC_22561347","title":"TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.","date":"2012","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22561347","citation_count":32,"is_preprint":false},{"pmid":"31964993","id":"PMC_31964993","title":"The E3 ubiquitin ligase TRIP12 participates in cell cycle progression and chromosome stability.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31964993","citation_count":30,"is_preprint":false},{"pmid":"18627766","id":"PMC_18627766","title":"TRIP12 functions as an E3 ubiquitin ligase of APP-BP1.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18627766","citation_count":30,"is_preprint":false},{"pmid":"22028794","id":"PMC_22028794","title":"The E3 ubiquitin ligase activity of Trip12 is essential for mouse embryogenesis.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22028794","citation_count":27,"is_preprint":false},{"pmid":"20699639","id":"PMC_20699639","title":"Reactivating the ARF-p53 axis in AML cells by targeting ULF.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20699639","citation_count":27,"is_preprint":false},{"pmid":"33824312","id":"PMC_33824312","title":"Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33824312","citation_count":26,"is_preprint":false},{"pmid":"33080340","id":"PMC_33080340","title":"Mild iron overload induces TRIP12-mediated degradation of YY1 to trigger hepatic inflammation.","date":"2020","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33080340","citation_count":26,"is_preprint":false},{"pmid":"20385357","id":"PMC_20385357","title":"The TRIP from ULF to ARF.","date":"2010","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/20385357","citation_count":16,"is_preprint":false},{"pmid":"36747006","id":"PMC_36747006","title":"The neurodevelopmental and facial phenotype in individuals with a TRIP12 variant.","date":"2023","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/36747006","citation_count":15,"is_preprint":false},{"pmid":"38341427","id":"PMC_38341427","title":"circEPB41L2 blocks the progression and metastasis in non-small cell lung cancer by promoting TRIP12-triggered PTBP1 ubiquitylation.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38341427","citation_count":13,"is_preprint":false},{"pmid":"24769896","id":"PMC_24769896","title":"Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24769896","citation_count":13,"is_preprint":false},{"pmid":"33963176","id":"PMC_33963176","title":"The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33963176","citation_count":12,"is_preprint":false},{"pmid":"25693655","id":"PMC_25693655","title":"Creating a gold standard surgical device: scientific discoveries leading to TVT and beyond: Ulf Ulmsten Memorial Lecture 2014.","date":"2015","source":"International urogynecology journal","url":"https://pubmed.ncbi.nlm.nih.gov/25693655","citation_count":12,"is_preprint":false},{"pmid":"36430143","id":"PMC_36430143","title":"Episignature Mapping of TRIP12 Provides Functional Insight into Clark-Baraitser Syndrome.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430143","citation_count":11,"is_preprint":false},{"pmid":"32424948","id":"PMC_32424948","title":"Novel de novo TRIP12 mutation reveals variable phenotypic presentation while emphasizing core features of TRIP12 variations.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/32424948","citation_count":8,"is_preprint":false},{"pmid":"36639831","id":"PMC_36639831","title":"Small molecule Z363 co-regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth.","date":"2023","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36639831","citation_count":8,"is_preprint":false},{"pmid":"38297686","id":"PMC_38297686","title":"Spectroscopic and imaging considerations of THz-TDS and ULF-Raman techniques towards practical security applications.","date":"2024","source":"Optics express","url":"https://pubmed.ncbi.nlm.nih.gov/38297686","citation_count":7,"is_preprint":false},{"pmid":"40613707","id":"PMC_40613707","title":"TRIP12's role in the governance of DNA polymerase β involvement in DNA damage response and repair.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/40613707","citation_count":7,"is_preprint":false},{"pmid":"37863914","id":"PMC_37863914","title":"Control of TGFβ signalling by ubiquitination independent function of E3 ubiquitin ligase TRIP12.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37863914","citation_count":6,"is_preprint":false},{"pmid":"36990278","id":"PMC_36990278","title":"Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36990278","citation_count":6,"is_preprint":false},{"pmid":"24961348","id":"PMC_24961348","title":"RNA-Seq analysis identifies aberrant RNA splicing of TRIP12 in acute myeloid leukemia patients at remission.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24961348","citation_count":5,"is_preprint":false},{"pmid":"36275919","id":"PMC_36275919","title":"Novel Synonymous and Frameshift Variants in the TRIP12 Gene Identified in 2 Chinese Patients With Intellectual Disability.","date":"2022","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36275919","citation_count":4,"is_preprint":false},{"pmid":"36672454","id":"PMC_36672454","title":"E3 Ubiquitin Ligase TRIP12 Controls Exit from Mitosis via Positive Regulation of MCL-1 in Response to Taxol.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672454","citation_count":4,"is_preprint":false},{"pmid":"39939725","id":"PMC_39939725","title":"Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39939725","citation_count":3,"is_preprint":false},{"pmid":"38924548","id":"PMC_38924548","title":"The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis.","date":"2024","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38924548","citation_count":3,"is_preprint":false},{"pmid":"40928944","id":"PMC_40928944","title":"Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40928944","citation_count":3,"is_preprint":false},{"pmid":"39155295","id":"PMC_39155295","title":"Engineered targeting OIP5 sensitizes bladder cancer to chemotherapy resistance via TRIP12-PPP1CB-YBX1 axis.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39155295","citation_count":2,"is_preprint":false},{"pmid":"39651249","id":"PMC_39651249","title":"Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39651249","citation_count":2,"is_preprint":false},{"pmid":"38706891","id":"PMC_38706891","title":"Inhibition of esophageal cancer progression through HACE1-TRIP12 interaction and associated RAC1 ubiquitination and degradation.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38706891","citation_count":2,"is_preprint":false},{"pmid":"40172777","id":"PMC_40172777","title":"The Role of a Novel TRIP12 Mutation in Intellectual Disability: A Molecular and Clinical Investigation in Multiplex Family.","date":"2025","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/40172777","citation_count":2,"is_preprint":false},{"pmid":"37108203","id":"PMC_37108203","title":"Analysis of Ku70 S155 Phospho-Specific BioID2 Interactome Identifies Ku Association with TRIP12 in Response to DNA Damage.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37108203","citation_count":2,"is_preprint":false},{"pmid":"39353003","id":"PMC_39353003","title":"High sensitivity measurement of ULF, VLF, and LF fields with a Rydberg-atom sensor.","date":"2024","source":"Optics letters","url":"https://pubmed.ncbi.nlm.nih.gov/39353003","citation_count":2,"is_preprint":false},{"pmid":"11776035","id":"PMC_11776035","title":"Immunolocalization of uterine luminal fluid protein (ULF-250) in rat uterus.","date":"2000","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11776035","citation_count":2,"is_preprint":false},{"pmid":"38645048","id":"PMC_38645048","title":"TRIP12 governs DNA Polymerase β involvement in DNA damage response and repair.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38645048","citation_count":1,"is_preprint":false},{"pmid":"33565064","id":"PMC_33565064","title":"[Intellectual disability due to heterozygous c.40C>T variant of TRIP12 gene in a patient].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33565064","citation_count":1,"is_preprint":false},{"pmid":"8980114","id":"PMC_8980114","title":"Characterization of a uterine luminal fluid protein ULF-250 using N-terminal microsequencing and RT-PCR identifies a novel estrogen-regulated gene in the rat uterus.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8980114","citation_count":1,"is_preprint":false},{"pmid":"40473626","id":"PMC_40473626","title":"The TRIP12 E3 ligase induces SWI/SNF component BRG1-β-catenin interaction to promote Wnt signaling.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40473626","citation_count":0,"is_preprint":false},{"pmid":"40947978","id":"PMC_40947978","title":"USP7 overexpression prevents the progression of clear cell renal cell carcinoma by enhancing pyroptosis via TRIP12 deubiquitination.","date":"2025","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40947978","citation_count":0,"is_preprint":false},{"pmid":"41098776","id":"PMC_41098776","title":"The E3 ubiquitin ligase Trip12 semi-selectively attenuates Wnt signaling.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41098776","citation_count":0,"is_preprint":false},{"pmid":"39484584","id":"PMC_39484584","title":"The E3 Ubiquitin Ligase Trip12 attenuates Wnt9a/Fzd9b signaling during hematopoietic stem cell development.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39484584","citation_count":0,"is_preprint":false},{"pmid":"41465129","id":"PMC_41465129","title":"Neurodevelopmental Phenotype Associated with TRIP12: Report of a Family Carrying the p.Asp1135Val Variant.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/41465129","citation_count":0,"is_preprint":false},{"pmid":"41660270","id":"PMC_41660270","title":"The TRIP12's intrinsically disordered region induces chromatin condensates and interferes with nuclear processes.","date":"2026","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41660270","citation_count":0,"is_preprint":false},{"pmid":"41611982","id":"PMC_41611982","title":"miR-381-3p suppresses pterygium progression by regulating HACE1/TRIP12-mediated ubiquitin-degradation of MCPIP1.","date":"2026","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/41611982","citation_count":0,"is_preprint":false},{"pmid":"40062706","id":"PMC_40062706","title":"Unraveling the Molecular and Clinical Consequences of an Intragenic TRIP12 Duplication Using Genomic and RNA Analyses.","date":"2025","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/40062706","citation_count":0,"is_preprint":false},{"pmid":"41413819","id":"PMC_41413819","title":"Novel TRIP12 variants in two Lebanese patients with neurodevelopmental delay.","date":"2025","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41413819","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.14.688426","title":"A Mass Spectrometry-Based Interactome Study on Anisomelic Acid and Its Effects on HPV16 E7","date":"2025-11-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.14.688426","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.29.620783","title":"Targeted disruption of linkage-specific ubiquitylation reveals a key role of K29-linked ubiquitylation in epigenome integrity","date":"2024-11-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.29.620783","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.02.610777","title":"Deep contrastive learning enables genome-wide virtual screening","date":"2024-09-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.02.610777","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.19.25338298","title":"Brain-age in ultra-low-field MRI: how well does it work?","date":"2025-10-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.19.25338298","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.10.25329262","title":"Feasibility and Validity of Ultra- Low-Field MRI for Measurement of Regional Infant Brain Volumes in Structures Associated with Antenatal Maternal Anemia","date":"2025-06-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.10.25329262","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30769,"output_tokens":5812,"usd":0.089744},"stage2":{"model":"claude-opus-4-6","input_tokens":9435,"output_tokens":4287,"usd":0.231525},"total_usd":0.321269,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"TRIP12 and UBR5, two HECT domain E3 ubiquitin ligases, control accumulation of RNF168 by promoting its degradation via ubiquitylation, thereby limiting spreading of histone ubiquitin conjugates (H2A-Ub) beyond DNA double-strand break sites and preventing hyperaccumulation of 53BP1 and BRCA1 at undamaged chromatin.\",\n      \"method\": \"siRNA depletion of TRIP12/UBR5, immunofluorescence of 53BP1/BRCA1/ubiquitin conjugates, western blot for RNF168 levels, DSB-induced focus formation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal depletion experiments with multiple orthogonal readouts, replicated across labs (>297 citations)\",\n      \"pmids\": [\"22884692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRIP12 HECT domain functions as the E3 ubiquitin ligase of the human ubiquitin fusion degradation (UFD) pathway, catalyzing in vitro ubiquitination of UFD substrates (including UBB+1) in conjunction with E1, E2, and E4 enzymes; the HECT domain possesses a noncovalent ubiquitin-binding site required for substrate recognition.\",\n      \"method\": \"In vitro ubiquitination assay, siRNA knockdown, cell death assays, cross-linking of HECT domain to ubiquitin moiety in vivo, complementation with HECT domain alone\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and cross-linking; multiple orthogonal methods in single paper\",\n      \"pmids\": [\"19028681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRIP12 interacts with APP-BP1 (NEDD8-activating enzyme subunit) specifically as a monomer (not as APP-BP1/Uba3 heterodimer), ubiquitinates it in vitro requiring E4 activity for polyubiquitination, and promotes its proteasomal degradation, thereby modulating neddylation of CUL1.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro ubiquitination assay, siRNA knockdown with western blot, neddylation assay of CUL1\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro ubiquitination reconstitution plus multiple cellular assays\",\n      \"pmids\": [\"18627766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The E3 ubiquitin ligase activity of Trip12 is indispensable for mouse embryogenesis; homozygous catalytic inactivation causes embryonic lethality with growth arrest and p16 upregulation; Trip12 targets BAF57 (SWI/SNF component) for degradation and regulates global gene expression.\",\n      \"method\": \"Homozygous knock-in mutation disrupting HECT catalytic activity, mouse embryology, ES cell growth and differentiation assays, western blot for BAF57 and p16\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined in vivo phenotype and molecular substrate identification\",\n      \"pmids\": [\"22028794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HUWE1 and TRIP12 function in parallel (additive stabilization upon double knockdown) during UFD substrate degradation; HUWE1 associates with both the UFD substrate Ub(G76V)-YFP and the 26S proteasome, acting late in the pathway.\",\n      \"method\": \"High-throughput siRNA imaging screen, single/double knockdown, pulse-chase degradation assays, co-immunoprecipitation with proteasome\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis by double knockdown; single lab but orthogonal approaches\",\n      \"pmids\": [\"23209776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRIP12 functions as an E3 ubiquitin ligase for USP7/HAUSP, controlling its protein stability; TRIP12 knockdown increases USP7-mediated stabilization of p53, 53BP1, and Chk1 and increases the G1 cell population, while TRIP12 overexpression phenocopies USP7 knockdown by increasing intra-S phase cells.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, western blot, cell cycle analysis by FACS\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, co-IP plus knockdown/overexpression with cell cycle phenotype\",\n      \"pmids\": [\"27800609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIP12 binds PARP1 via its central PAR-binding WWE domain and, via its C-terminal HECT domain, catalyzes polyubiquitylation of PARP1 triggering proteasomal degradation; loss of TRIP12 elevates PARP1 levels, causing increased PARPi-induced cytotoxic PARP1 trapping, replication stress, and cell death.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination, siRNA knockdown, PARP1 trapping assay, cell viability/clonogenic survival, domain mapping (WWE and HECT)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — domain-level mechanistic dissection with in vitro ubiquitination plus multiple cellular phenotypes\",\n      \"pmids\": [\"32755579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIP12 promotes PROTAC/CRL2VHL-induced degradation of neo-substrate BRD4 (but not endogenous HIF-1α) by associating with BRD4 via CRL2VHL and specifically assembling K29-linked ubiquitin chains that facilitate formation of K29/K48-branched ubiquitin chains, accelerating K48 chain elongation and proteasomal degradation.\",\n      \"method\": \"Mass spectrometry-based ubiquitin linkage analysis, in vitro ubiquitination, siRNA/CRISPR knockout, PROTAC degradation assays, domain mapping, apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with MS-based chain linkage determination and multiple orthogonal cellular assays\",\n      \"pmids\": [\"33567268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIP12 interacts with glucocerebrosidase (GCase) and ubiquitinates it at lysine 293, triggering proteasomal degradation; TRIP12 overexpression causes premature GCase degradation, α-synuclein accumulation, and mitochondrial dysfunction; conditional TRIP12 knockout or knockdown promotes GCase expression and blocks dopaminergic neurodegeneration in PD models.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination, site-directed mutagenesis (K293), TRIP12 conditional KO mouse, in vivo knockdown, α-syn PFF model, western blot, human PD brain tissue analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-specific ubiquitination with mutagenesis, in vivo KO and knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"34644545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIP12 ubiquitinates FBW7 preferentially on K404/K412 (via SCFFBW7 self-ubiquitylation) and additionally assembles K11-linked branched ubiquitin chains on FBW7 via its HECT domain; this branched ubiquitylation is required for FBW7 proteasomal degradation; TRIP12 inactivation causes FBW7 accumulation and consequent MCL1 degradation, sensitizing cells to anti-tubulin chemotherapy.\",\n      \"method\": \"shRNA library screen, mass spectrometry, in vitro ubiquitination, site-directed mutagenesis of FBW7 K404/K412, CRISPR knockout, western blot, cell viability assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — MS-defined chain linkage, mutagenesis, in vitro ubiquitination, genetic epistasis\",\n      \"pmids\": [\"33824312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIP12 expression is regulated during the cell cycle correlating with its nuclear localization; an N-terminal intrinsically disordered region (IDR) mediates euchromatin binding; TRIP12 controls duration of DNA replication (mitotic entry) independent of its catalytic activity, and is required for mitotic progression and chromosome stability.\",\n      \"method\": \"Cell cycle synchronization, western blot, immunofluorescence/live imaging, chromatin fractionation, siRNA knockdown, catalytic mutant complementation, FACS for chromosome stability\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional consequence; catalytic mutant separates enzymatic from non-enzymatic roles\",\n      \"pmids\": [\"31964993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"WARS (tryptophanyl-tRNA synthetase) tryptophanylates TRIP12 at lysine 1136, activating its E3 ligase activity toward NFATc1 (a PD-1 transcription activator), promoting NFATc1 degradation and reducing PD-1 surface expression on CD8+ T cells; SIRT1 de-tryptophanylates TRIP12 and reverses these effects.\",\n      \"method\": \"Mass spectrometry identification of tryptophanylation, site-directed mutagenesis (K1136), co-immunoprecipitation, flow cytometry for surface PD-1, syngeneic mouse tumor models\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel PTM identified by MS with mutagenesis validation and downstream functional consequence\",\n      \"pmids\": [\"34326168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIP12 is identified by immunoprecipitation-coupled LC-MS/MS as an E3 ubiquitin ligase that binds and ubiquitinates the transcription factor YY1, leading to its proteasomal degradation; this triggers the HNF4α/miR-122/CCL2 pathway promoting hepatic inflammation during mild iron overload.\",\n      \"method\": \"Immunoprecipitation coupled LC-MS/MS, co-immunoprecipitation, western blot, siRNA knockdown, overexpression in vivo\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — substrate identification by IP-MS with functional validation in vivo; single lab\",\n      \"pmids\": [\"33080340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIP12 controls TGFβ signaling in a manner completely independent of its E3 ubiquitin ligase activity; instead, TRIP12 recruits SMURF2 to SMAD4, promoting inhibitory monoubiquitination of SMAD4; catalytically inactive C1959A mutant rescues TRIP12-KO phenotype; this function is evolutionarily conserved (Drosophila ctrip/Medea epistasis confirmed).\",\n      \"method\": \"CRISPR/Cas9 KO, catalytic mutant complementation (C1959A), co-immunoprecipitation of SMURF2-SMAD4, TGFβ reporter assays, Drosophila genetic epistasis, 3D intestinal organoids, migration assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — catalytic mutant demonstrates ligase-independent function; epistasis in two organisms; multiple orthogonal methods\",\n      \"pmids\": [\"37863914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIP12 ubiquitylates DNA polymerase β (Polβ) in a BER complex-dependent manner, controlling Polβ cellular levels and chromatin loading; TRIP12-mediated Polβ ubiquitylation promotes Polβ foci formation at radiation-induced DNA damage sites, directing BER over DSB repair; excessive TRIP12-mediated Polβ engagement increases DSB formation and radiation sensitivity.\",\n      \"method\": \"Ubiquitination assays, chromatin fractionation, siRNA/CRISPR depletion, Polβ foci formation (immunofluorescence), radiation sensitivity/clonogenic assays, co-immunoprecipitation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods; single lab but rigorous mechanistic dissection\",\n      \"pmids\": [\"40613707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIP12 ubiquitylates BRG1 (SWI/SNF component) in the presence of Wnt signaling, promoting BRG1 interaction with β-catenin in the nucleus to recruit SWI/SNF to Wnt target genes; TRIP12 depletion attenuates Wnt signaling; genetic epistasis places TRIP12 downstream of the β-catenin destruction complex.\",\n      \"method\": \"CRISPR/siRNA depletion in Drosophila, zebrafish, mouse organoids, human cells; co-immunoprecipitation of BRG1-β-catenin; ubiquitination assays; genetic epistasis; Wnt reporter assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis across multiple organisms, co-IP, ubiquitination assays, multiple orthogonal systems\",\n      \"pmids\": [\"40473626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIP12 functions as a ubiquitin chain elongation factor that cooperates with CUL3KEAP1 to ensure robust NRF2 degradation; TRIP12 activity accelerates silencing of the oxidative stress response as ROS are cleared but limits NRF2 activation during stress.\",\n      \"method\": \"CRISPR KO, NRF2 degradation assays, ubiquitin chain assays, oxidative stress/ROS assays, cell viability after oxeiptosis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic chain elongation assays; single lab\",\n      \"pmids\": [\"40928944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIP12 ubiquitinates Frizzled-9b (Fzd9b) at K437 in its third intracellular loop, targeting it for lysosomal degradation, reducing Fzd9b membrane surface expression and dampening Wnt9a/Fzd9b signaling; this semi-selective action affects hematopoietic stem cell proliferation in zebrafish.\",\n      \"method\": \"Site-directed mutagenesis of Fzd9b K437, ubiquitination assays, flow cytometry for surface Fzd9b, zebrafish HSC proliferation assay, lysosome inhibitor experiments, co-immunoprecipitation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-specific ubiquitination with mutagenesis plus in vivo zebrafish functional readout\",\n      \"pmids\": [\"41098776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"K29-linked ubiquitylation of SUV39H1 (H3K9me3 methyltransferase) is catalyzed by TRIP12 and reversed by TRABID; K29-linked ubiquitylation is essential for proteasomal degradation of SUV39H1 even in the presence of extensive K48-linked ubiquitylation; disruption of this modification deregulates the H3K9me3 landscape.\",\n      \"method\": \"Ubiquitin replacement cell-based strategy, MS-based linkage analysis, TRIP12 KO/depletion, in vitro ubiquitination, H3K9me3 ChIP, SUV39H1 stability assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution and MS linkage analysis; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2024.10.29.620783\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIP12 suppresses EMT through inhibiting ZEB1/2 gene expression; TRIP12-depleted cells gain mesenchymal traits (loss of polarity, increased motility, anoikis resistance); ZEB1/2 depletion rescues EMT markers in TRIP12-depleted cells, placing ZEB1/2 downstream of TRIP12.\",\n      \"method\": \"siRNA knockdown of TRIP12, RNA-seq, ZEB1/2 double KD rescue, cell polarity assays, migration assays, anoikis assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis by rescue experiment with defined cellular phenotypes\",\n      \"pmids\": [\"33963176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p16 overexpression downregulates TRIP12, which leads to increased RNF168 levels, repressed DNA damage repair, increased 53BP1 foci, and enhanced radiosensitivity; TRIP12 inhibition further radiosensitizes cells, establishing a p16→TRIP12→RNF168 regulatory axis.\",\n      \"method\": \"p16 overexpression/shRNA knockdown, western blot for TRIP12 and RNF168, immunofluorescence for 53BP1 foci, clonogenic survival assays, neutral comet assay, cycloheximide half-life assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined epistatic pathway with multiple orthogonal cellular readouts\",\n      \"pmids\": [\"27425591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIP12 associates with Ku70 at sites of DNA double-strand breaks; this association is enhanced upon ionizing radiation and is specific to the Ku70 S155 phosphorylated form, as identified by BioID2 proximity labeling and validated by proximity ligation assay and co-immunoprecipitation.\",\n      \"method\": \"BioID2 proximity labeling, SAINTexpress analysis, proximity ligation assay (PLA), co-immunoprecipitation after IR treatment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — proximity labeling with PLA validation; no functional consequence established for TRIP12\",\n      \"pmids\": [\"37108203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"The N-terminal intrinsically disordered region (IDR) of TRIP12 drives formation of dynamic chromatin condensates enriched in heterochromatin marks through electrostatic interactions and bridging-induced phase separation; these condensates alter cell cycle progression, genome accessibility, and transcription independently of TRIP12's ubiquitin ligase activity.\",\n      \"method\": \"Live-cell imaging, FRAP, IDR deletion/mutation constructs, heterochromatin mark staining, ATAC-seq, transcriptome analysis, catalytic mutant controls\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional consequences; catalytic mutant separates enzymatic from phase-separation roles\",\n      \"pmids\": [\"41660270\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRIP12 is a HECT-domain E3 ubiquitin ligase that assembles multiple ubiquitin chain topologies (K29, K11, K48, and branched chains) to target diverse substrates—including RNF168, PARP1, FBW7, GCase, USP7, YY1, Polβ, BRG1, Fzd9b, NRF2, and UFD pathway substrates—for proteasomal or lysosomal degradation, while also exerting ligase-independent functions by recruiting SMURF2 to SMAD4 to suppress TGFβ signaling and by using its N-terminal IDR to drive chromatin condensate formation, thereby regulating DNA damage responses, cell cycle progression, Wnt signaling, and the oxidative stress response.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TRIP12 is a HECT-domain E3 ubiquitin ligase that assembles diverse ubiquitin chain topologies—including K29, K11, K48, and branched chains—to target a broad substrate repertoire for proteasomal or lysosomal degradation, thereby governing DNA damage responses, cell cycle progression, Wnt signaling, TGF-β signaling, and the oxidative stress response. Key substrates include RNF168 (limiting histone ubiquitin spreading at DNA break sites) [PMID:22884692], PARP1 (modulating PARP inhibitor sensitivity) [PMID:32755579], FBW7 (via K11-branched chains controlling MCL1 stability) [PMID:33824312], glucocerebrosidase (regulating α-synuclein accumulation and dopaminergic neuron survival) [PMID:34644545], BRG1 (recruiting SWI/SNF to β-catenin at Wnt target genes) [PMID:40473626], and NRF2 (cooperating with CUL3-KEAP1 to silence the oxidative stress response) [PMID:40928944]. TRIP12 also performs ligase-independent functions: its N-terminal intrinsically disordered region drives chromatin condensate formation that alters genome accessibility and cell cycle timing [PMID:41660270], and it recruits SMURF2 to SMAD4 to suppress TGF-β signaling independently of catalytic activity [PMID:37863914]. Homozygous loss of TRIP12 catalytic activity causes embryonic lethality in mice with growth arrest and p16 upregulation [PMID:22028794].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing TRIP12 as the dedicated E3 ligase of the ubiquitin fusion degradation (UFD) pathway resolved how aberrant ubiquitin-fusion proteins are recognized and cleared, and revealed a noncovalent ubiquitin-binding site in the HECT domain required for substrate engagement.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution with HECT domain mutagenesis, cross-linking, and siRNA knockdown in human cells\",\n      \"pmids\": [\"19028681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E4 cofactor identity for UFD pathway elongation not fully defined\", \"Structural basis of the noncovalent ubiquitin-binding site unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstration that TRIP12 ubiquitinates APP-BP1 (a NEDD8-activating enzyme subunit) and controls its proteasomal turnover linked TRIP12 to regulation of the neddylation cascade, expanding its role beyond UFD substrates.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro ubiquitination, and siRNA knockdown with CUL1 neddylation readout\",\n      \"pmids\": [\"18627766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRIP12 regulation of neddylation has physiological consequences in vivo not tested\", \"E4 requirement for APP-BP1 polyubiquitination not molecularly defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic inactivation of Trip12 catalytic activity in mice established that its E3 ligase function is essential for embryogenesis, identified BAF57 (SWI/SNF subunit) as an in vivo substrate, and linked TRIP12 loss to p16 de-repression.\",\n      \"evidence\": \"Homozygous knock-in catalytic-dead mutation in mice; ES cell assays; western blot for BAF57 and p16\",\n      \"pmids\": [\"22028794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p16 is a direct or indirect TRIP12 target not resolved\", \"Tissue-specific requirements during embryogenesis not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that TRIP12 (and UBR5) limit RNF168 accumulation to prevent excessive histone ubiquitylation spreading at DNA damage sites established TRIP12 as a rheostat for the DNA damage response, explaining how 53BP1 and BRCA1 foci are confined to break-proximal chromatin.\",\n      \"evidence\": \"siRNA depletion of TRIP12/UBR5 with immunofluorescence for 53BP1/BRCA1/ubiquitin conjugates and RNF168 protein level measurement\",\n      \"pmids\": [\"22884692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRIP12 directly ubiquitinates RNF168 in vitro not shown in this study\", \"Relative contributions of TRIP12 versus UBR5 not fully deconvolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of USP7 as a TRIP12 substrate linked TRIP12 to control of p53 stability and cell cycle transitions, revealing that TRIP12 indirectly tunes the p53 axis by degrading a key deubiquitinase.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, and FACS cell cycle analysis\",\n      \"pmids\": [\"27800609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro ubiquitination of USP7 by TRIP12 not demonstrated\", \"Direct ubiquitination sites on USP7 not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapping TRIP12's WWE domain as the PAR-binding module that targets PARP1 for HECT-dependent ubiquitylation and degradation explained how TRIP12 loss sensitizes cells to PARP inhibitors through increased PARP1 trapping, providing a pharmacologically actionable mechanism.\",\n      \"evidence\": \"Domain mapping, in vitro ubiquitination, PARP1 trapping assay, clonogenic survival after PARPi treatment\",\n      \"pmids\": [\"32755579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chain linkage specificity on PARP1 not determined\", \"Whether PAR binding is required for all TRIP12 substrates unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Characterization of cell-cycle-dependent TRIP12 expression and its N-terminal IDR-mediated euchromatin association revealed a catalytic-activity-independent role in controlling DNA replication timing and mitotic entry, separating enzymatic from structural functions.\",\n      \"evidence\": \"Cell cycle synchronization, chromatin fractionation, catalytic mutant complementation, live imaging\",\n      \"pmids\": [\"31964993\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which IDR binding to chromatin controls replication timing unknown\", \"Whether IDR function requires specific chromatin readers not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that TRIP12 assembles K29-linked chains that seed K29/K48-branched ubiquitin chains on substrates (shown for PROTAC-recruited BRD4) established TRIP12 as a ubiquitin chain architecture specialist that accelerates proteasomal targeting through branched chain formation.\",\n      \"evidence\": \"Mass spectrometry-based ubiquitin linkage analysis, in vitro ubiquitination reconstitution, CRISPR KO, PROTAC degradation assays\",\n      \"pmids\": [\"33567268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether K29/K48 branching is a general feature of all TRIP12 substrates not known\", \"Structural basis for K29 linkage preference not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of glucocerebrosidase (GCase) K293 as a TRIP12 ubiquitination site linked TRIP12 to Parkinson's disease pathogenesis: TRIP12-driven GCase degradation causes α-synuclein accumulation and dopaminergic neurodegeneration, reversible by TRIP12 conditional knockout.\",\n      \"evidence\": \"Site-directed mutagenesis, conditional KO mouse, α-synuclein PFF model, human PD brain tissue analysis\",\n      \"pmids\": [\"34644545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRIP12 inhibition is therapeutically viable for PD not tested in primates\", \"Upstream signals controlling TRIP12-GCase interaction unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealing that TRIP12 builds K11-branched ubiquitin chains on FBW7 (at K404/K412) to drive its degradation connected TRIP12 to indirect stabilization of MCL1 and chemotherapy resistance, providing a mechanistic basis for TRIP12 inactivation as a sensitization strategy.\",\n      \"evidence\": \"shRNA library screen, MS-based linkage analysis, in vitro ubiquitination, FBW7 mutagenesis, CRISPR KO\",\n      \"pmids\": [\"33824312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether K11-branched chains are assembled by TRIP12 alone or require an E4 cofactor not fully resolved\", \"Quantitative contribution of FBW7 self-ubiquitylation priming versus TRIP12-initiated ubiquitylation unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that TRIP12 suppresses TGF-β signaling entirely independently of its catalytic activity—by recruiting SMURF2 to monoubiquitinate SMAD4—established a paradigm-shifting non-enzymatic adaptor function conserved from Drosophila to mammals.\",\n      \"evidence\": \"Catalytic mutant C1959A rescue of TRIP12-KO phenotype, co-IP of SMURF2-SMAD4, TGF-β reporter assays, Drosophila ctrip/Medea genetic epistasis\",\n      \"pmids\": [\"37863914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface between TRIP12 and SMURF2 not structurally resolved\", \"Whether this adaptor function extends to other signaling pathways unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Establishing that TRIP12 depletion induces EMT through ZEB1/2 upregulation positioned TRIP12 as a suppressor of mesenchymal transition, though whether this occurs through direct ZEB1/2 ubiquitination or an indirect transcriptional mechanism remains open.\",\n      \"evidence\": \"siRNA knockdown, RNA-seq, ZEB1/2 double-KD rescue of EMT markers, migration and anoikis assays\",\n      \"pmids\": [\"33963176\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZEB1/2 are direct TRIP12 substrates not determined\", \"Contribution of TRIP12 ligase activity versus adaptor function to EMT suppression not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that TRIP12 ubiquitylates Pol-β in a BER-complex-dependent manner, promoting its chromatin loading at damage sites to favor base excision repair over DSB repair, revealed TRIP12 as a repair pathway choice factor whose overactivity paradoxically increases DSBs and radiosensitivity.\",\n      \"evidence\": \"Ubiquitination assays, chromatin fractionation, Pol-β foci formation after IR, clonogenic survival, CRISPR depletion\",\n      \"pmids\": [\"40613707\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin chain type on Pol-β not identified\", \"Whether this mechanism operates in non-irradiated cells during normal BER not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showing that TRIP12 ubiquitylates BRG1 to promote its interaction with β-catenin at Wnt target genes—conserved across Drosophila, zebrafish, mouse, and human cells—placed TRIP12 as a positive regulator of canonical Wnt signaling acting downstream of the β-catenin destruction complex.\",\n      \"evidence\": \"CRISPR/siRNA in four model organisms, co-IP of BRG1-β-catenin, ubiquitination assays, Wnt reporter assays, genetic epistasis\",\n      \"pmids\": [\"40473626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chain linkage type on BRG1 not determined\", \"Whether TRIP12-mediated BRG1 ubiquitination is degradative or non-degradative not fully clarified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of TRIP12 as a ubiquitin chain elongation factor cooperating with CUL3-KEAP1 to degrade NRF2 explained how the oxidative stress response is rapidly silenced once ROS are cleared, adding NRF2 to the catalog of TRIP12 substrates requiring E3–E3 cooperation.\",\n      \"evidence\": \"CRISPR KO, NRF2 degradation and ubiquitin chain assays, oxidative stress and oxeiptosis cell viability assays\",\n      \"pmids\": [\"40928944\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chain linkage specificity on NRF2 by TRIP12 not determined\", \"Whether TRIP12 functions similarly with other CRL E3 ligases beyond CUL3-KEAP1 and CRL2-VHL not explored\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstration that the TRIP12 N-terminal IDR drives chromatin condensate formation through bridging-induced phase separation, independently of catalytic activity, unified earlier observations of IDR-dependent chromatin binding with a biophysical mechanism and showed these condensates alter genome accessibility and transcription.\",\n      \"evidence\": \"Live-cell imaging, FRAP, IDR deletion/mutation constructs, ATAC-seq, transcriptome analysis, catalytic mutant controls\",\n      \"pmids\": [\"41660270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether condensate formation is required for TRIP12's ligase-dependent functions unknown\", \"Biophysical parameters (valency, saturation concentration) not quantitatively defined\", \"In vivo relevance of condensates in organismal physiology not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A complete structural model of full-length TRIP12 is lacking, and the rules governing substrate selectivity among its many targets—particularly how WWE-domain PAR binding, IDR-mediated chromatin association, and HECT-domain chain-type specificity are coordinated—remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of full-length TRIP12 available\", \"Mechanisms determining K29 versus K11 versus K48 chain selectivity per substrate unknown\", \"How TRIP12 ligase-dependent and ligase-independent functions are spatiotemporally coordinated in vivo not understood\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 7, 8, 9, 14, 15, 16, 17]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 7, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 22]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [10, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 6, 14, 20]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 10, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2, 7, 8, 9, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 15, 17]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RNF168\",\n      \"PARP1\",\n      \"FBW7\",\n      \"GBA\",\n      \"SMAD4\",\n      \"SMURF2\",\n      \"BRG1\",\n      \"USP7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}